pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 13·1 min read
save

Podcast explores the limits of "blue zones" concept in aging research

May 13, 2026·read at STAT ↗Neutral

On a recent First Opinion podcast, medical journalist Shelley Wood and cardiologist Eric Topol discussed the "blue zones" concept and its relevance to aging research.

They traced the idea back to mountain villages in Sardinia, Italy, noting that many historical records were destroyed during World War II, which raises questions about the reliability of the longevity claims.

The guests acknowledged that, while the original data may be flawed, the blue zones narrative still promotes useful ideas about lifestyle and community that can inform the current longevity craze, even as commercial hype threatens its scientific credibility.

Listeners are encouraged to subscribe to the weekly First Opinion Podcast for further insights.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: What can ‘blue zones’ really teach us about aging?”

read at STAT ↗
405 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
MOUNTAIN2

related stories

  • 2d agoOpinion: Is Milton Friedman to blame for America’s health care woes?STAT
  • Oct 8The Nobel boys club (again)STAT
  • Oct 8A mother-daughter quest to find fellow members of an ultra-rare genetic communitySTAT
  • Oct 7ER visits from people born outside the U.S. dropped after ICE raidsSTAT
  • Sep 22‘It’s just survival now’: Why is almost a third of Boston’s life sciences lab space sitting vacant?Fierce Biotech